Bortesun

Bortesun

bortezomib

Manufacturer:

Sun Pharma

Distributor:

DKLL

Marketer:

Ranbaxy
Concise Prescribing Info
Contents
Bortezomib
Indications/Uses
Adult patients w/ multiple myeloma & mantle cell lymphoma.
Dosage/Direction for Use
Individualized dosage. Recommended starting dose: 1.3 mg/m2 administered either as a 3-5 sec IV bolus or SC inj. Multiple myeloma Retreatment: Start at the last tolerated dose. Moderate or severe hepatic impairment Use a lower starting dose.
Contraindications
Hypersensitivity to bortezomib or mannitol. Intrathecal administration.
Special Precautions
Discontinue use if peripheral neuropathy occurs. Pre-existing severe neuropathy; hypotension; dehydration. History of syncope. Concomitant use w/ antihypertensives.
Adverse Reactions
Nausea, diarrhea, thrombocytopenia, neutropenia, peripheral neuropathy, fatigue, neuralgia, anemia, leukopenia, constipation, vomiting, lymphopenia, rash, pyrexia & anorexia.
Drug Interactions
Concomitant use w/ strong CYP3A4 inhibitors & inducers.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01XG01 - bortezomib ; Belongs to the class of proteasome inhibitors. Used in the treatment of cancer.
Presentation/Packing
Form
Bortesun powd for inj 3.5 mg
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in